ArticlePediatric nephrology (Berlin, Germany)2021
Impact of steroids and steroid-sparing agents on quality of life in children with nephrotic syndrome.
Article in Pediatric nephrology (Berlin, Germany), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 20 citations in OpenAlex.
- Health-related quality of life of children with first onset steroid-sensitive nephrotic syndrome.European journal of pediatrics · 2023Trial
- Machine learning prediction of childhood nephrotic syndrome outcomes.Pediatric nephrology (Berlin, Germany) · 2026Observational
- Mental health among caregivers of children with nephrotic syndrome: a prospective cohort study.Pediatric nephrology (Berlin, Germany) · 2026Observational
- Establishing core outcomes and minimal clinically important differences for childhood steroid sensitive nephrotic syndrome clinical trials: results from a Delphi consensus process.Pediatric nephrology (Berlin, Germany) · 2026Article
- Serum Podocalyxin Level as a Potential Biomarker for Diagnosis of Nephrotic Syndrome and Prediction of Steroid Response.Medeniyet medical journal · 2025Article
- Prolonged remission after cyclophosphamide or tacrolimus treatment in childhood nephrotic syndrome: a cohort study.Pediatric nephrology (Berlin, Germany) · 2025Article
- Assessment of health-related quality of life of children with idiopathic nephrotic syndrome and their caregivers in China.Health and quality of life outcomes · 2024Article
- Impact of childhood nephrotic syndrome on obesity and growth: a prospective cohort study.Pediatric nephrology (Berlin, Germany) · 2024Article
- Family functioning and quality of life among children with nephrotic syndrome during the first pandemic wave.Pediatric nephrology (Berlin, Germany) · 2023Article
- Autosomal Recessive Congenital Ichthyosis and Steroid-Resistant Nephrotic Syndrome due to Homozygous Mutation in theJournal of pediatric genetics · 2022Article
- Comparison of rituximab, cyclophosphamide, and tacrolimus as first steroid-sparing agents for complicated relapsing/steroid-dependent nephrotic syndrome in children: an evaluation of the health-related quality of life.Archives of medical science : AMS · 2022Article
- Design of a User-Centered Electronic Health Tool for Glomerular Disease Management.Glomerular diseasesArticle
- Quality of Life of Children with Idiopathic Nephrotic Syndrome.Indian journal of nephrologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSteroids and/or steroid-sparing medications are commonly used for nephrotic syndrome treatment; however, the impact of these medications on health-related quality of life over time is not well described.
methodsLongitudinal cohort is up to 5 years where children were assessed with baseline and annual Pediatric Quality of Life Inventory questionnaire. A mixed-effects linear regression determined differences in scores among children receiving steroids and/or steroid-sparing agents for at least 30 days compared with those not on medication at 1, 3, 6, and 12 months prior to assessment.
resultsAmong 295 children, 64% were male, with a median age of 3.7 (interquartile range [IQR], 2.7, 5.9) years at diagnosis, and comprised 25% Europeans, 40% South Asians, and 8% East/Southeast Asians. Adjusted HRQOL scores were reduced among children taking steroids and steroid-sparing agents among 705 HRQOL measures (median 2 [IQR, 1, 3] per child). Compared to children without medication, steroid and steroid-sparing agent use up to 12 months prior to assessment were associated with an overall HRQOL drop of 3.17 (95% confidence interval [CI], - 5.25, - 1.08) and 3.18 (95% CI, - 5.24, - 1.12), respectively, after adjustment. Functioning domain scores were reduced by 4.41 points (95% CI, - 6.57, - 2.25) in children on steroids, whereas fatigue domain scores were reduced by 5.47 points (95% CI, - 9.28, - 1.67) in children on steroid-sparing agents after adjustment.
conclusionsHRQOL is consistently decreased in children receiving steroids and steroid-sparing agents, with differential effects on functioning and fatigue. Counseling families on possible effects of prolonged treatment periods is important in the management of childhood nephrotic syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.